Table Info

Table 2.

Ca²⁺/CaMKs and their functions in different cancers

Components	Cancer type	Effects	References
CaMKK	Lung cancer	Tumor metastasis	[93]
	Prostate cancer	Tumor growth and castration resistance	[94]
	Glioma	Migration, invasion, and proliferation	[95]
CaMKI	Breast cancer	Control of cell cycle progression	[96]
CaMKII	Glioma	Migration and invasion	[97]
	Melanoma and hepatoma	Reprogramming of macrophages	[98]
	Prostate cancer	Inhibition of cancer growth and invasion, and induction of apoptosis	[99]
CaMKIV	Hepatic cancer	Cancer cell growth	[100]

Declarations

Author contributions

TX, SC, JH, and ZL conceptualized the manuscript; TX, SC, and JH wrote this review; PW, HW, and ZL revised the manuscript. All authors have read and approved the submitted version of the manuscript.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. Bone metastases. Nat Rev Dis Primers. 2020;6:83. [DOI] [PubMed]

Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64. [DOI] [PubMed]

Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101. [PubMed]

Kahn D, Weiner GJ, Ben-Haim S, Ponto LL, Madsen MT, Bushnell DL, et al. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood. 1994;83:958–63. Erratum in: Blood. 1994;84:3602. [DOI] [PubMed]

Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986;261:12665–74. [DOI] [PubMed]

Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57–62. [DOI] [PubMed]

Bai H, Zhu H, Yan Q, Shen X, Lu X, Wang J, et al. TRPV2-induced Ca²⁺-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma. Cell Commun Signal. 2018;16:68. [DOI] [PubMed] [PMC]

Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97:1566–71. [DOI] [PubMed] [PMC]

Chu GC, Chung LW. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 2014;33:497–509. [DOI] [PubMed] [PMC]

10.

Chen X, Pei Z, Peng H, Zheng Z. Exploring the molecular mechanism associated with breast cancer bone metastasis using bioinformatic analysis and microarray genetic interaction network. Medicine (Baltimore). 2018;97:e12032. [DOI] [PubMed] [PMC]

11.

Ardura JA, Álvarez-Carrión L, Gutiérrez-Rojas I, Alonso V. Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms. Cancers (Basel). 2020;12:1071. [DOI] [PubMed] [PMC]

12.

Wang H, Tian L, Liu J, Goldstein A, Bado I, Zhang W, et al. The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell. 2018;34:823–39.e7. [DOI] [PubMed] [PMC]

13.

Bootman MD. Calcium signaling. Cold Spring Harb Perspect Biol. 2012;4:a011171. [DOI] [PubMed] [PMC]

14.

Wu L, Lian W, Zhao L. Calcium signaling in cancer progression and therapy. FEBS J. 2021;288:6187–205. [DOI] [PubMed]

15.

Patergnani S, Danese A, Bouhamida E, Aguiari G, Previati M, Pinton P, et al. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. Int J Mol Sci. 2020;21:8323. [DOI] [PubMed] [PMC]

16.

Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011;11:609–18. [DOI] [PubMed]

17.

Clapham DE. Calcium signaling. Cell. 2007;131:1047–58. [DOI] [PubMed]

18.

Bootman MD, Collins TJ, Peppiatt CM, Prothero LS, MacKenzie L, De Smet P, et al. Calcium signalling—an overview. Semin Cell Dev Biol. 2001;12:3–10. [DOI] [PubMed]

19.

Conigrave AD, Ward DT. Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways. Best Pract Res Clin Endocrinol Metab. 2013;27:315–31. [DOI] [PubMed]

20.

Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517–29. [DOI] [PubMed]

21.

Okada H, Okabe K, Tanaka S. Finely-tuned calcium oscillations in osteoclast differentiation and bone resorption. Int J Mol Sci. 2020;22:180. [DOI] [PubMed] [PMC]

22.

Yang Z, Yue Z, Ma X, Xu Z. Calcium homeostasis: a potential vicious cycle of bone metastasis in breast cancers. Front Oncol. 2020;10:293. [DOI] [PubMed] [PMC]

23.

Marchi S, Giorgi C, Galluzzi L, Pinton P. Ca²⁺ fluxes and cancer. Mol Cell. 2020;78:1055–69. [DOI] [PubMed]

24.

Mikoshiba K, Furuichi T, Miyawaki A. Structure and function of IP₃ receptors. Semin Cell Biol. 1994;5:273–81. [DOI] [PubMed]

25.

Roberts-Thomson SJ, Chalmers SB, Monteith GR. The calcium-signaling toolkit in cancer: remodeling and targeting. Cold Spring Harb Perspect Biol. 2019;11:a035204. [DOI] [PubMed] [PMC]

26.

Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011;3:a003947. [DOI] [PubMed] [PMC]

27.

He L, Si G, Huang J, Samuel ADT, Perrimon N. Mechanical regulation of stem-cell differentiation by the stretch-activated Piezo channel. Nature. 2018;555:103–6. [DOI] [PubMed] [PMC]

28.

Moran MM, McAlexander MA, Bíró T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10:601–20. [DOI] [PubMed]

29.

Koivisto AP, Belvisi MG, Gaudet R, Szallasi A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat Rev Drug Discov. 2022;21:41–59. [DOI] [PubMed] [PMC]

30.

Wu LJ, Sweet TB, Clapham DE. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev. 2010;62:381–404. [DOI] [PubMed] [PMC]

31.

Gautier M, Dhennin-Duthille I, Ay AS, Rybarczyk P, Korichneva I, Ouadid-Ahidouch H. New insights into pharmacological tools to TR(i)P cancer up. Br J Pharmacol. 2014;171:2582–92. [DOI] [PubMed] [PMC]

32.

Sun Y, Ye C, Tian W, Ye W, Gao YY, Feng YD, et al. TRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis. Oncogenesis. 2021;10:67. [DOI] [PubMed] [PMC]

33.

Villalobos C, Hernández-Morales M, Gutiérrez LG, Núñez L. TRPC1 and ORAI1 channels in colon cancer. Cell Calcium. 2019;81:59–66. [DOI] [PubMed]

34.

Lin DC, Zheng SY, Zhang ZG, Luo JH, Zhu ZL, Li L, et al. TRPC3 promotes tumorigenesis of gastric cancer via the CNB2/GSK3β/NFATc2 signaling pathway. Cancer Lett. 2021;519:211–25. [DOI] [PubMed]

35.

Wang Y, Qi YX, Qi Z, Tsang SY. TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway. Cancers (Basel). 2019;11:558. [DOI] [PubMed] [PMC]

36.

Chen Z, Tang C, Zhu Y, Xie M, He D, Pan Q, et al. TrpC5 regulates differentiation through the Ca²⁺/Wnt5a signalling pathway in colorectal cancer. Clin Sci (Lond). 2017;131:227–37. [DOI] [PubMed]

37.

Ma X, Chen Z, Hua D, He D, Wang L, Zhang P, et al. Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc Natl Acad Sci U S A. 2014;111:6389–94. [DOI] [PubMed] [PMC]

38.

Xu J, Yang Y, Xie R, Liu J, Nie X, An J, et al. The NCX1/TRPC6 complex mediates TGFβ-driven migration and invasion of human hepatocellular carcinoma cells. Cancer Res. 2018;78:2564–76. [DOI] [PubMed]

39.

Jardin I, Diez-Bello R, Lopez JJ, Redondo PC, Salido GM, Smani T, et al. TRPC6 channels are required for proliferation, migration and invasion of breast cancer cell lines by modulation of Orai1 and Orai3 surface exposure. Cancers (Basel). 2018;10:331. [DOI] [PubMed] [PMC]

40.

Shi Y, Ding X, He ZH, Zhou KC, Wang Q, Wang YZ. Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut. 2009;58:1443–50. [DOI] [PubMed]

41.

Kato S, Shiozaki A, Kudou M, Shimizu H, Kosuga T, Ohashi T, et al. TRPV2 promotes cell migration and invasion in gastric cancer via the transforming growth factor-β signaling pathway. Ann Surg Oncol. 2022;29:2944–56. [DOI] [PubMed]

42.

Xie R, Xu J, Xiao Y, Wu J, Wan H, Tang B, et al. Calcium promotes human gastric cancer via a novel coupling of calcium-sensing receptor and TRPV4 channel. Cancer Res. 2017;77:6499–512. [DOI] [PubMed]

43.

Xu X, Li N, Wang Y, Yu J, Mi J. Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. Cancer Lett. 2021;519:150–60. [DOI] [PubMed]

44.

Hall DP, Cost NG, Hegde S, Kellner E, Mikhaylova O, Stratton Y, et al. TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 2014;26:738–53. [DOI] [PubMed] [PMC]

45.

Sagredo AI, Sagredo EA, Cappelli C, Báez P, Andaur RE, Blanco C, et al. TRPM4 regulates AKT/GSK3-β activity and enhances β-catenin signaling and cell proliferation in prostate cancer cells. Mol Oncol. 2018;12:151–65. [DOI] [PubMed] [PMC]

46.

Liu L, Wu N, Wang Y, Zhang X, Xia B, Tang J, et al. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K/AKT oncogenic signaling. J Exp Clin Cancer Res. 2019;38:106. [DOI] [PubMed] [PMC]

47.

Chen Y, Liu L, Xia L, Wu N, Wang Y, Li H, et al. TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation. J Exp Clin Cancer Res. 2022;41:44. [DOI] [PubMed] [PMC]

48.

Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, et al. Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest. 2002;82:1755–64. [DOI] [PubMed]

49.

Peng JB, Brown EM, Hediger MA. Epithelial Ca²⁺ entry channels: transcellular Ca²⁺ transport and beyond. J Physiol. 2003;551:729–40. [DOI] [PubMed] [PMC]

50.

Raphaël M, Lehen’kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Vanden Abeele F, et al. TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc Natl Acad Sci U S A. 2014;111:E3870–9. [DOI] [PubMed] [PMC]

51.

Jimenez I, Prado Y, Marchant F, Otero C, Eltit F, Cabello-Verrugio C, et al. TRPM channels in human diseases. Cells. 2020;9:2604. [DOI] [PubMed] [PMC]

52.

Sun Y, Selvaraj S, Varma A, Derry S, Sahmoun AE, Singh BB. Increase in serum Ca²⁺/Mg²⁺ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels. J Biol Chem. 2013;288:255–63. [DOI] [PubMed] [PMC]

53.

Yang F, Cai J, Zhan H, Situ J, Li W, Mao Y, et al. Suppression of TRPM7 inhibited hypoxia-induced migration and invasion of androgen-independent prostate cancer cells by enhancing RACK1-mediated degradation of HIF-1α. Oxid Med Cell Longev. 2020;2020:6724810. [DOI] [PubMed] [PMC]

54.

Meng X, Cai C, Wu J, Cai S, Ye C, Chen H, et al. TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer Lett. 2013;333:96–102. [DOI] [PubMed]

55.

Middelbeek J, Visser D, Henneman L, Kamermans A, Kuipers AJ, Hoogerbrugge PM, et al. TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation. Oncotarget. 2015;6:8760–76. [DOI] [PubMed] [PMC]

56.

Ong EC, Nesin V, Long CL, Bai CX, Guz JL, Ivanov IP, et al. A TRPC1 protein-dependent pathway regulates osteoclast formation and function. J Biol Chem. 2013;288:22219–32. [DOI] [PubMed] [PMC]

57.

Masuyama R, Vriens J, Voets T, Karashima Y, Owsianik G, Vennekens R, et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab. 2008;8:257–65. [DOI] [PubMed]

58.

van der Eerden BC, Hoenderop JG, de Vries TJ, Schoenmaker T, Buurman CJ, Uitterlinden AG, et al. The epithelial Ca²⁺ channel TRPV5 is essential for proper osteoclastic bone resorption. Proc Natl Acad Sci U S A. 2005;102:17507–12. [DOI] [PubMed] [PMC]

59.

Ma J, Zhu L, Zhou Z, Song T, Yang L, Yan X, et al. The calcium channel TRPV6 is a novel regulator of RANKL-induced osteoclastic differentiation and bone absorption activity through the IGF-PI3K-AKT pathway. Cell Prolif. 2021;54:e12955. [DOI] [PubMed] [PMC]

60.

Soboloff J, Rothberg BS, Madesh M, Gill DL. STIM proteins: dynamic calcium signal transducers. Nat Rev Mol Cell Biol. 2012;13:549–65. [DOI] [PubMed] [PMC]

61.

Várnai P, Hunyady L, Balla T. STIM and Orai: the long-awaited constituents of store-operated calcium entry. Trends Pharmacol Sci. 2009;30:118–28. [DOI] [PubMed] [PMC]

62.

Courjaret R, Machaca K. STIM and Orai in cellular proliferation and division. Front Biosci (Elite Ed). 2012;4:331–41. [DOI] [PubMed]

63.

Sabbioni S, Barbanti-Brodano G, Croce CM, Negrini M. GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res. 1997;57:4493–7. [PubMed]

64.

Motiani RK, Abdullaev IF, Trebak M. A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J Biol Chem. 2010;285:19173–83. [DOI] [PubMed] [PMC]

65.

Faouzi M, Hague F, Potier M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H. Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. J Cell Physiol. 2011;226:542–51. [DOI] [PubMed]

66.

Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816–26. [DOI] [PubMed]

67.

Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells - over and over and over again. Nat Cell Biol. 2002;4:E97–100. [DOI] [PubMed]

68.

Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34. [DOI] [PubMed]

69.

Köhler M, Hirschberg B, Bond CT, Kinzie JM, Marrion NV, Maylie J, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273:1709–14. [DOI] [PubMed]

70.

Chantôme A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Guéguinou M, et al. Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73:4852–61. [DOI] [PubMed]

71.

Girault A, Haelters JP, Potier-Cartereau M, Chantome A, Pinault M, Marionneau-Lambot S, et al. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Curr Cancer Drug Targets. 2011;11:1111–25. [DOI] [PubMed]

72.

Zhang Z, Xu Q, Song C, Mi B, Zhang H, Kang H, et al. Serum- and glucocorticoid-inducible kinase 1 is essential for osteoclastogenesis and promotes breast cancer bone metastasis. Mol Cancer Ther. 2020;19:650–60. [DOI] [PubMed]

73.

Eylenstein A, Gehring EM, Heise N, Shumilina E, Schmidt S, Szteyn K, et al. Stimulation of Ca²⁺-channel Orai1/STIM1 by serum- and glucocorticoid-inducible kinase 1 (SGK1). FASEB J. 2011;25:2012–21. [DOI] [PubMed] [PMC]

74.

Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67:821–70. [DOI] [PubMed] [PMC]

75.

Bhargava A, Saha S. T-type voltage gated calcium channels: a target in breast cancer? Breast Cancer Res Treat. 2019;173:11–21. [DOI] [PubMed]

76.

Ohkubo T, Yamazaki J. T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int J Oncol. 2012;41:267–75. [DOI] [PubMed]

77.

Hu S, Li L, Huang W, Liu J, Lan G, Yu S, et al. CAV3.1 knockdown suppresses cell proliferation, migration and invasion of prostate cancer cells by inhibiting AKT. Cancer Manag Res. 2018;10:4603–14. [DOI] [PubMed] [PMC]

78.

Maiques O, Macià A, Moreno S, Barceló C, Santacana M, Vea A, et al. Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma. Br J Dermatol. 2017;176:1247–58. [DOI] [PubMed]

79.

Plotkin LI, Bellido T. Beyond gap junctions: Connexin43 and bone cell signaling. Bone. 2013;52:157–66. [DOI] [PubMed] [PMC]

80.

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528:93–8. [DOI] [PubMed]

81.

Chin D, Means AR. Calmodulin: a prototypical calcium sensor. Trends Cell Biol. 2000;10:322–8. [DOI] [PubMed]

82.

O’Day DH, Taylor RJ, Myre MA. Calmodulin and calmodulin binding proteins in Dictyostelium: a primer. Int J Mol Sci. 2020;21:1210. [DOI] [PubMed] [PMC]

83.

Iwakawa M, Ando K, Ohkawa H, Koike S, Chen YJ. A murine model for bone marrow metastasis established by an i.v. injection of C-1300 neuroblastoma in A/J mice. Clin Exp Metastasis. 1994;12:231–7. [DOI] [PubMed]

84.

Brzozowski JS, Skelding KA. The multi-functional calcium/calmodulin stimulated protein kinase (CaMK) family: emerging targets for anti-cancer therapeutic intervention. Pharmaceuticals (Basel). 2019;12:8. [DOI] [PubMed] [PMC]

85.

Hook SS, Means AR. Ca²⁺/CaM-dependent kinases: from activation to function. Annu Rev Pharmacol Toxicol. 2001;41:471–505. [DOI] [PubMed]

86.

Green MF, Scott JW, Steel R, Oakhill JS, Kemp BE, Means AR. Ca²⁺/calmodulin-dependent protein kinase kinase β is regulated by multisite phosphorylation. J Biol Chem. 2011;286:28066–79. [DOI] [PubMed] [PMC]

87.

Shifman JM, Choi MH, Mihalas S, Mayo SL, Kennedy MB. Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) is activated by calmodulin with two bound calciums. Proc Natl Acad Sci U S A. 2006;103:13968–73. [DOI] [PubMed] [PMC]

88.

Frigo DE, Howe MK, Wittmann BM, Brunner AM, Cushman I, Wang Q, et al. CaM kinase kinase β-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res. 2011;71:528–37. [DOI] [PubMed] [PMC]

89.

Shima T, Mizokami A, Miyagi T, Kawai K, Izumi K, Kumaki M, et al. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer. Prostate. 2012;72:1789–801. [DOI] [PubMed]

90.

Dadwal UC, Chang ES, Sankar U. Androgen receptor-CaMKK2 axis in prostate cancer and bone microenvironment. Front Endocrinol (Lausanne). 2018;9:335. [DOI] [PubMed] [PMC]

91.

Cary RL, Waddell S, Racioppi L, Long F, Novack DV, Voor MJ, et al. Inhibition of Ca²⁺/calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation. J Bone Miner Res. 2013;28:1599–610. [DOI] [PubMed] [PMC]

92.

Racioppi L, Noeldner PK, Lin F, Arvai S, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses. J Biol Chem. 2012;287:11579–91. [DOI] [PubMed] [PMC]

93.

Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y, et al. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell. 2018;69:87–99.e7. [DOI] [PubMed] [PMC]

94.

Wang N, Yao M, Xu J, Quan Y, Zhang K, Yang R, et al. Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of AKT. Clin Cancer Res. 2015;21:4676–85. [DOI] [PubMed]

95.

Liu DM, Wang HJ, Han B, Meng XQ, Chen MH, Yang DB, et al. CAMKK2, regulated by promoter methylation, is a prognostic marker in diffuse gliomas. CNS Neurosci Ther. 2016;22:518–24. [DOI] [PubMed] [PMC]

96.

Rodriguez-Mora OG, LaHair MM, McCubrey JA, Franklin RA. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 2005;65:5408–16. [DOI] [PubMed]

97.

Yu-Ju Wu C, Chen CH, Lin CY, Feng LY, Lin YC, Wei KC, et al. CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro Oncol. 2020;22:253–66. [DOI] [PubMed] [PMC]

98.

Dai X, Meng J, Deng S, Zhang L, Wan C, Lu L, et al. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. Theranostics. 2020;10:3049–63. [DOI] [PubMed] [PMC]

99.

Tan H, Zhang G, Yang X, Jing T, Shen D, Wang X. Peimine inhibits the growth and motility of prostate cancer cells and induces apoptosis by disruption of intracellular calcium homeostasis through Ca²⁺/CaMKII/JNK pathway. J Cell Biochem. 2020;121:81–92. [DOI] [PubMed]

100.

Lin F, Marcelo KL, Rajapakshe K, Coarfa C, Dean A, Wilganowski N, et al. The camKK2/camKIV relay is an essential regulator of hepatic cancer. Hepatology. 2015;62:505–20. [DOI] [PubMed] [PMC]

101.

Buchthal B, Lau D, Weiss U, Weislogel JM, Bading H. Nuclear calcium signaling controls methyl-CpG-binding protein 2 (MeCP2) phosphorylation on serine 421 following synaptic activity. J Biol Chem. 2012;287:30967–74. [DOI] [PubMed] [PMC]

102.

Li H, Zhong X, Chau KF, Santistevan NJ, Guo W, Kong G, et al. Cell cycle-linked MeCP2 phosphorylation modulates adult neurogenesis involving the Notch signalling pathway. Nat Commun. 2014;5:5601. [DOI] [PubMed] [PMC]

103.

Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer. 2009;9:810–20. [DOI] [PubMed] [PMC]

104.

Di Giorgio E, Hancock WW, Brancolini C. MEF2 and the tumorigenic process, hic sunt leones. Biochim Biophys Acta Rev Cancer. 2018;1870:261–73. [DOI] [PubMed]

105.

Mamaeva OA, Kim J, Feng G, McDonald JM. Calcium/calmodulin-dependent kinase II regulates notch-1 signaling in prostate cancer cells. J Cell Biochem. 2009;106:25–32. [DOI] [PubMed]

106.

Shin MK, Kim MK, Bae YS, Jo I, Lee SJ, Chung CP, et al. A novel collagen-binding peptide promotes osteogenic differentiation via Ca²⁺/calmodulin-dependent protein kinase II/ERK/AP-1 signaling pathway in human bone marrow-derived mesenchymal stem cells. Cell Signal. 2008;20:613–24. [DOI] [PubMed]

107.

Wang L, Fang D, Xu J, Luo R. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020;20:1059. [DOI] [PubMed] [PMC]

108.

Seales EC, Micoli KJ, McDonald JM. Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J Cell Biochem. 2006;97:45–55. [DOI] [PubMed]

109.

Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003;17:2205–32. [DOI] [PubMed]

110.

Liang Q, Wang Y, Lu Y, Zhu Q, Xie W, Tang N, et al. RANK promotes colorectal cancer migration and invasion by activating the Ca²⁺-calcineurin/NFATC1-ACP5 axis. Cell Death Dis. 2021;12:336. [DOI] [PubMed] [PMC]

111.

Deng R, Huang JH, Wang Y, Zhou LH, Wang ZF, Hu BX, et al. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Mol Cancer. 2020;19:122. [DOI] [PubMed] [PMC]

112.

Jin H, Wang C, Jin G, Ruan H, Gu D, Wei L, et al. Regulator of calcineurin 1 gene isoform 4, down-regulated in hepatocellular carcinoma, prevents proliferation, migration, and invasive activity of cancer cells and metastasis of orthotopic tumors by inhibiting nuclear translocation of NFAT1. Gastroenterology. 2017;153:799–811.e33. [DOI] [PubMed]

113.

Liu Y, Zhang Y, Min J, Liu LL, Ma NQ, Feng YM, et al. Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer. Tumour Biol. 2010;31:199–207. [DOI] [PubMed]

114.

Ma NQ, Liu LL, Min J, Wang JW, Jiang WF, Liu Y, et al. The effect of down regulation of calcineurin Aα by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis. Clin Exp Metastasis. 2011;28:765–78. [DOI] [PubMed]

115.

Leach K, Hannan FM, Josephs TM, Keller AN, Møller TC, Ward DT, et al. International Union of Basic and Clinical Pharmacology. CVIII. Calcium-sensing receptor nomenclature, pharmacology, and function. Pharmacol Rev. 2020;72:558–604. [DOI] [PubMed] [PMC]

116.

Goltzman D, Hendy GN. The calcium-sensing receptor in bone—mechanistic and therapeutic insights. Nat Rev Endocrinol. 2015;11:298–307. [DOI] [PubMed]

117.

Tuffour A, Kosiba AA, Zhang Y, Peprah FA, Gu J, Shi H. Role of the calcium-sensing receptor (CaSR) in cancer metastasis to bone: identifying a potential therapeutic target. Biochim Biophys Acta Rev Cancer. 2021;1875:188528. [DOI] [PubMed]

118.

Joeckel E, Haber T, Prawitt D, Junker K, Hampel C, Thüroff JW, et al. High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol Cancer. 2014;13:42. [DOI] [PubMed] [PMC]

119.

Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM. Ca²⁺-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endocrinol Metab. 2001;281:E1267–74. [DOI] [PubMed]

120.

Liu L, Fan Y, Chen Z, Zhang Y, Yu J. CaSR induces osteoclast differentiation and promotes bone metastasis in lung adenocarcinoma. Front Oncol. 2020;10:305. [DOI] [PubMed] [PMC]

121.

Das S, Clézardin P, Kamel S, Brazier M, Mentaverri R. The CaSR in pathogenesis of breast cancer: a new target for early stage bone metastases. Front Oncol. 2020;10:69. [DOI] [PubMed] [PMC]

122.

Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018;68:377–86. [DOI] [PubMed]

123.

Liao J, Schneider A, Datta NS, McCauley LK. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 2006;66:9065–73. [DOI] [PubMed]